恩替卡韦治疗慢性乙型肝炎肝纤维化疗效的研究

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To evaluate the efficacy of entecavir anti-fibrosis treatment in chronic hepatitis B(CHB) with real-time shear wave elastography and ultrasound quantitative score. Methods: Eighty-seven CHB patients with antiviral treatment indications were enrolled. They were grouped by liver pathological staging before treatment. Real-time shear wave elastography and ultrasound quantitative score were compared with pathological staging between groups before treatment. Real-time shear wave elastography was compared with ultrasound quantitative score within groups after 96 weeks entecavir treatment. Results: Eighty-seven CHB patients were divided into three groups: group A(S0, S1) 12 patients, group B(S2, S3) 64 patients, and group C(S4) 11 patients. The parameters of stiffness and ultrasound quantitative score increased gradually with liver fibrosis exacerbation． The parameters of stiffness and ultrasound quantitative score of each pathological stage had statistically significant difference between groups. Both of these parameters were well correlated with the pathological change on the liver fibrosis． The areas under the curve for stiffness and ultrasound quantitative score were 0.89 and 0.78, respectively． The parameters of stiffness and ultrasound quantitative score obviously decreased after 96 weeks treatment vs before. The parameters of stiffness and ultrasound quantitative score of each pathological stage had statistically significant difference within groups. The parameters of stiffness and ultrasound quantitative score in three groups were group A＜group B＜group C. Conclusion: Real-time shear wave elastography and ultrasound quantitative score could be used to evaluate the efficacy of entecavir anti-fibrosis treatment in CHB.

Key words： Hepatitis B, chronic Liver cirrhosis Ultrasonography, Doppler, color

PACS:	Ｒ512.62
	Ｒ445.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DINＧ　Ｙang
	AN Zi-ying
	WANG Sui-jing
	DOU Xiao-guang

Cite this article:

DINＧ　Ｙang,AN Zi-ying,WANG Sui-jing, et al. Efficacy evaluation of entecavir anti-fibrosis treatment in chronic hepatitis B with#br# real-time shear wave elastography and ultrasound quantitative score[J]. JOURNAL OF CHINA MEDICAL IMAGING, 2016, 27(6): 407-410.

URL:

http://www.jccmi.com.cn/EN/ OR http://www.jccmi.com.cn/EN/Y2016/V27/I6/407

[1]Brenner DA． Molecular pathologenesis of liver fibrosis[J]． Trans Am Clin Climatol Assoc, 2009, 120: 361-368．
[2]Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B[J]. Hepatology, 2010, 52(3): 886-93.
[3]Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis[J]. Best Pract Res Clin Gastroenterol, 2011, 25(2): 195-206.
[4]Terrault NA, Bzowej NH, Chang KM, et al. AASLD Guidelines for Treatment of Chronic Hepatitis B[J]. Hepatology, 2016, 63(1): 261-283.
[5]中华医学会肝病学分会，中华医学会感染病学分会. 慢性乙型肝炎防治指南[J]. 中华肝脏病杂志，2011，19（1）：13-24.
[6]李建志，李洁，熊春梅，等． Fibroscan测定与超声影像学检查在诊断慢性乙肝相关肝纤维化中的价值[J]．山东大学学报：医学版，2012，50（10）：115－118．
[7]张玲荣，郝彦琴，任姣龙，等. 慢性乙肝患者肝纤维化与肝硬度、超声量化指标、血清肝纤维化指标的相关性[J]．山西医科大学学报，2015，46（1）：45－48．
[8]王金锐，徐荣．肝纤维化诊断及疗效评估共识[J]．中华肝脏病杂志，2009，10（5）：327-328．
[9]Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity[J]. Vaccine, 2012, 30(12): 2212-2219.
[10]Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2012, 380(9859): 2095-2128.
[11]Parsons CJ, Takashima M, Rippe RA． Molecular mechanisms of hepatic fibrogenesis[J]． J Gastroenterol Hepatol, 2007, 22(Suppl 1): S79-S84．
[12]Saleh HA, Abu-Ｒashed AH． Liver biopsy remains the gold standard for evaluation of chronic hepatitis and fibrosis[J]． J Gastrointestin Liver Dis, 2007, 16(4): 425－426．
[13]Jeong JY, Kim TY, Sohn JH, et al. Real time shear wave elastography in chronic liver diseases: Accuracy for predicting liver fibrosis, in comparison with serum markers[J]. World J Gastroenterol, 2014, 20(38): 13920-13929.
[14]Jung KS, Kim SU． Clinical applications of transient elastography[J]． Clin Mol Hepatol, 2012, 18(2): 163－173．
[15]Muller M, Gennisson JL, Deffieux T, et al. Quantitative viscoelasticity mapping of human liver using supersonic shear imaging: preliminary in vivo feasibility study[J]. Ultrasound Med Biol, 2009, 35(2): 219-229.
[16]Ling W, Lu Q, Quan J, et al. Assessment of impact factors on shear wave based liver stiffness measurement[J]. Eur J Radiol, 2013, 82(2): 335-341.